#For patients
Written for adults considering a peptide as part of their health management.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.
Semaglutide bloating and nausea: trial data
Nausea, bloating and diarrhoea top the side-effect list for semaglutide. Here is what the STEP trial data says about how common they are and why.
What semaglutide does to daily life in MASH
A new ESSENCE analysis puts a number on how people with MASH feel on semaglutide: a small EQ-5D utility gain, and why payers will care about it.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.
How semaglutide produces weight loss
Semaglutide works mainly in the brain, suppressing appetite via GLP-1 signalling. Here is what the STEP trials found and what stops when the drug stops.
Tirzepatide in youth: first real-world data
A study of 74 youth prescribed tirzepatide at three clinics found lower blood sugar and BMI. What can the first real-world numbers actually show?
Do other diabetes drugs stop on a GLP-1?
In 3,660 adults starting a GLP-1 or tirzepatide, the count of other glucose-lowering drugs fell for 17.2% of patients and rose for 44.0%.
Semaglutide and MASH: what ESSENCE found
Semaglutide has a licensed indication for MASH, the inflamed form of fatty liver disease. Here is what the ESSENCE trial showed, and what it has not.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
What a high IGF-1 result means
A high or high-normal IGF-1 result does not make tesamorelin safer. Here is what the label, human trials, and evidence gaps actually say.
Peptides for sleep and recovery: a primer
Ipamorelin and CJC-1295 act on the GH axis that drives slow-wave sleep. Here is what the research shows and where it runs out.